![]() ![]() |
|
| The site of the Melanoma Care Coalition: Fostering an Interdisciplinary Approach to Melanoma Care | |||||||
|
Continuing Medical Education Information Instructions for Participation To receive up to 1.5 AMA PRA category 1 credits for this activity:
Target Audience Dermatologists, dermatologic surgeons, surgical and medical oncologists, oncology nurses, primary care physicians, and other health care professionals who treat or screen for melanoma. Learning Objectives
Accreditation and Credit Designation The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The University of Pittsburgh School of Medicine designates this continuing medical education activity for a maximum of 1.5 category 1 credits towards the AMA Physician’s Recognition Award*. Each physician should claim only those credits that he/she actually spent in the educational activity. *Other healthcare professionals are awarded 0.15 continuing education units (CEUs), which are equal to 1.5 contact hours. We gratefully acknowledge an educational grant from Schering-Plough in support of this program. Faculty and Disclosure Douglas S. Reintgen, MD Director, Lakeland Regional Cancer Center Lakeland, Florida *No financial relationships to disclose Merrick I. Ross, MD Professor of Surgical Oncology, University of Texas M.D. Anderson Cancer Center Houston, Texas *No financial relationships to disclose Rosemary Giuliano, ARNP, MSN Associate Director, Cancer Screening Lakeland Regional Cancer Center Lakeland, Florida *Speakers’ Bureau, Schering-Plough Corporation Bruce J. Averbook, MD Associate Professor of Surgery Metro Health Medical Center Case Western Reserve University Cleveland, Ohio *Speakers’ Bureau, Schering Oncology Biotech Marc S. Ernstoff, MD Professor of Medicine Dartmouth-Hitchcock Medical Center Lebanon, New Hampshire *Grant/research support, Chiron Inc., Point Therapeutics, Pfizer Inc. Faculty for this activity have been required to disclose all financial or other relationships with pharmaceutical companies, biomedical device manufacturers, and other healthcare-related for-profit entities. The faculty acknowledges the discussion of off-label use of pharmaceuticals, including high-dose interferon alfa-2b and reverse transcriptase polymerase chain reaction analysis of lymph nodes. Date of Original Release Expiration Date Date of Last Review Disclaimer Privacy Policy Security Collection and use of your personal information PharmAdura does not transfer, sell, or share personal information with outside parties. PharmAdura will not otherwise disclose personal information unless required to in a legal process. RDCME staff members review individual test results to the extent necessary to record and track participant's credits. If you have any questions or comments on this click here. Contacting the Provider CME Services implemented in accordance with the policies of the ACCME | ||||||
| Last Modified 5/13/2008 |
| ||||||
| Copyright 2007 PharmAdura, LLC. | System Requirements | Privacy |